Novo's GLP-1 analog beats Lilly's in Type II diabetes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said both doses of subcutaneous semaglutide (NN9535) led to superior reductions on the primary endpoint measuring HbA1c compared to Trulicity dulaglutide from Eli Lilly and Co. (NYSE:LLY) in the Phase IIIb SUSTAIN 7 trial to treat Type II diabetes.

Next quarter, Novo expects a decision from FDA and an opinion from EMA's CHMP on its regulatory applications for semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog. Lilly's Trulicity is a GLP-1 receptor (GLP-1R; GLP1R) agonist...